Frunevetmab in Cats

Frunevetmab is the generic name for Solensia, a prescription monthly injection used to control pain associated with osteoarthritis in cats. It was approved by the U.S. Food and Drug Administration on January 13, 2022, and it remains the first FDA-approved treatment specifically labeled for osteoarthritis pain control in cats. That matters because feline arthritis is common, often underdiagnosed, and can be hard to manage with oral medications alone.

For many cats, arthritis shows up as subtle changes rather than obvious limping. A pet parent may notice less jumping, stiffness after rest, trouble using stairs, reduced grooming, irritability, or reluctance to be handled. Frunevetmab is not a cure for arthritis, and it does not rebuild damaged cartilage. Instead, it helps reduce pain signaling so some cats move more comfortably and engage more normally at home.

This medication is given by your vet as a subcutaneous injection, usually every 28 to 30 days. Some cats improve within days to a few weeks, while others need more than one monthly dose before the benefit is clear. Response can vary, so your vet may combine frunevetmab with weight management, home changes, rehab, or other pain-control options depending on your cat’s age, kidney status, mobility, and overall goals of care.

Because this is a biologic medication rather than a traditional pain pill, it can be a useful option for cats that are difficult to medicate by mouth or that need a different approach to chronic pain management. It still requires monitoring, though. Your vet may recommend rechecks, baseline lab work, and ongoing assessment of mobility, appetite, skin changes, and overall quality of life.

Frunevetmab is a monoclonal antibody designed specifically for cats. It targets nerve growth factor, often shortened to NGF. In arthritic joints, NGF is involved in pain signaling, peripheral sensitization, and neurogenic inflammation. By binding NGF, frunevetmab blocks its effects and reduces the signaling that tells the nervous system a joint is painful.

This mechanism is different from nonsteroidal anti-inflammatory drugs, or NSAIDs. NSAIDs mainly work by reducing inflammatory pathways, while frunevetmab focuses on the NGF pain pathway. That difference is one reason your vet may consider it when a cat needs chronic pain support but oral NSAID use is limited, not tolerated, or needs to be minimized. In some cases, vets may use multimodal therapy, meaning frunevetmab is paired with other treatments rather than used alone.

The FDA approval package describes frunevetmab as a felinized immunoglobulin G monoclonal antibody. In field studies, cats receiving frunevetmab had better owner-reported and veterinary-assessed pain outcomes than control cats, although the degree of improvement varied by time point and by study. In practical terms, that means many cats improve, but not every cat responds the same way or on the same timeline.

Because it is species-specific and long-acting, frunevetmab is given as an injection at the clinic instead of a daily home medication. That can be a major advantage for pet parents whose cats resist pills or whose daily medication routine is stressful. Still, your vet will want to confirm that arthritis is truly the main source of pain before starting treatment, since weakness, neurologic disease, heart disease, and other conditions can also change mobility.

Frunevetmab is generally well tolerated, but side effects do occur. In the FDA field study, commonly reported reactions included vomiting, injection-site pain, diarrhea, abnormal behavior or behavioral changes, reduced appetite, lethargy, dermatitis, alopecia, pruritus, and scabbing on the head or neck. VCA also notes appetite loss, anxiety, and ear infections among effects seen in trials or post-approval use. Most reactions are mild to moderate, but any new symptom after an injection deserves a call to your vet.

Skin changes are one of the more recognizable patterns with this medication. Some cats develop itching, scabs, hair loss, or dermatitis, often around the head, neck, or ears. Gastrointestinal signs such as vomiting or diarrhea can also happen. In the FDA confirmatory field study, vomiting was reported in 13.2% of treated cats, diarrhea in 6.6%, dermatitis in 6.0%, alopecia in 5.5%, pruritus in 3.8%, and scabbing on the head or neck in 3.3%.

Allergic reactions are considered uncommon but important. Cats with known hypersensitivity to frunevetmab should not receive it. If your cat develops facial swelling, hives, trouble breathing, collapse, or sudden severe weakness after treatment, see your vet immediately. Because this is a long-acting injectable medication, side effects cannot be reversed by stopping a daily pill, so prompt communication matters.

Long-term use beyond the periods studied in approval trials still calls for thoughtful monitoring. Your vet may recommend blood work, urinalysis, or recheck exams, especially in older cats or those with kidney disease and other chronic conditions. If your cat seems more itchy, less interested in food, more withdrawn, or less mobile after an injection, let your vet know rather than assuming it is part of aging.

Frunevetmab is given by subcutaneous injection at your veterinary clinic, typically once every 28 to 30 days. The FDA approval documents and Merck Veterinary Manual describe a labeled dose of about 1.0 mg/kg, with a practical dosing range of roughly 1 to 2.8 mg/kg depending on the vial size and the cat’s body weight. In the marketed product, cats weighing 2.5 to 7 kg receive 1 mL, and cats weighing 7.1 to 14 kg receive 2 mL of the 7 mg/mL solution.

This medication is not intended for home administration by pet parents. Your vet gives the injection, tracks your cat’s response, and adjusts the overall pain plan if needed. If your cat is receiving vaccines at the same visit, VCA advises using a different injection site. If a monthly dose is missed, contact your vet to reschedule rather than doubling up or trying to change the interval on your own.

Improvement may be seen within a few days to a few weeks after the first injection, but some cats need more than one month before the benefit is obvious. That delayed or gradual response is important to discuss up front so expectations stay realistic. Your vet may ask you to monitor jumping, stair use, litter box access, grooming, sleep posture, and willingness to play between visits.

Frunevetmab should not be used in breeding, pregnant, or lactating cats. It is also not labeled for cats under 5.5 pounds, which is about 2.5 kg. Before starting treatment, your vet may recommend baseline blood work and urinalysis, especially for senior cats or cats with other medical problems, so the pain plan fits the whole patient rather than the arthritis alone.

No formal drug interactions have been clearly established for frunevetmab in cats, but that does not mean interactions are impossible. VCA notes that drug interactions have not been reported at this time. During safety studies, cats received a range of other products, including parasiticides, antibiotics, antifungals, antidepressants, antiemetics, corticosteroids, NSAIDs, vaccines, immunotherapy, antihistamines, and other antipruritics without obvious interaction signals.

Merck notes that a drug-drug interaction between anti-NGF monoclonal antibodies and NSAIDs is not known to occur in dogs and cats, and some patients may benefit from both. Even so, combination therapy should be individualized. Cats often have multiple age-related conditions, and the safest plan depends on kidney values, hydration, appetite, blood pressure, and how much pain relief is actually needed.

Your vet should know about every medication and supplement your cat receives, including joint supplements, CBD products, gabapentin, steroids, flea and tick preventives, and any recent injections or vaccines. That full list helps your vet decide whether frunevetmab fits best as a stand-alone option or as part of multimodal care.

Caution is also reasonable in cats with significant underlying disease, in cats receiving other monoclonal antibody therapies, and in cats whose mobility changes may not be caused by arthritis alone. If your cat has chronic kidney disease, neurologic disease, diabetes, heart disease, or unexplained weight loss, your vet may recommend additional workup before continuing monthly injections.